Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

BACKGROUND Platelets are believed to play a part in the ischemic complications of coronary angioplasty, such as abrupt closure of the coronary vessel during or soon after the procedure. Accordingly, we evaluated the effect of a chimeric monoclonal-antibody Fab fragment (c7E3 Fab) directed against the platelet glycoprotein IIb/IIIa receptor, in patients undergoing angioplasty who were at high risk for ischemic complications. This receptor is the final common pathway for platelet aggregation. METHODS In a prospective, randomized, double-blind trial, 2099 patients treated at 56 centers received a bolus and an infusion of placebo, a bolus of c7E3 Fab and an infusion of placebo, or a bolus and an infusion of c7E3 Fab. They were scheduled to undergo coronary angioplasty or atherectomy in high-risk clinical situations involving severe unstable angina, evolving acute myocardial infarction, or high-risk coronary morphologic characteristics. The primary study end point consisted of any of the following: death, nonfatal myocardial infarction, unplanned surgical revascularization, unplanned repeat percutaneous procedure, unplanned implantation of a coronary stent, or insertion of an intraaortic balloon pump for refractory ischemia. The numbers of end-point events were tabulated for 30 days after randomization. RESULTS As compared with placebo, the c7E3 Fab bolus and infusion resulted in a 35 percent reduction in the rate of the primary end point (12.8 vs. 8.3 percent, P = 0.008), whereas a 10 percent reduction was observed with the c7E3 Fab bolus alone (12.8 vs. 11.5 percent, P = 0.43). The reduction in the number of events with the c7E3 Fab bolus and infusion was consistent across the end points of unplanned revascularization procedures and nonfatal myocardial infarction. Bleeding episodes and transfusions were more frequent in the group given the c7E3 Fab bolus and infusion than in the other two groups. CONCLUSIONS Ischemic complications of coronary angioplasty and atherectomy were reduced with a monoclonal antibody directed against the platelet IIb/IIIa glycoprotein receptor, although the risk of bleeding was increased.

[1]  H. Weisman,et al.  Randomized Trial of a GPIIb/IIIa Platelet Receptor Blocker in Refractory Unstable Angina , 1994, Circulation.

[2]  Thomas J. Ryan,et al.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). , 1993, Journal of the American College of Cardiology.

[3]  R. Califf,et al.  Long-term outcome following successful reopening of abrupt closure after coronary angioplasty. , 1993, The American journal of cardiology.

[4]  R. Califf,et al.  Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study Group. , 1993, Journal of the American College of Cardiology.

[5]  R. Califf,et al.  Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein llb/llla in patients undergoing elective coronary angioplasty , 1993, Coronary artery disease.

[6]  L. Klein,et al.  Does the AHA/ACC task force grading system predict outcome in multivessel coronary angioplasty? , 1992, Catheterization and cardiovascular diagnosis.

[7]  A. Muñoz,et al.  Transmission of Retroviruses from Seronegative Donors by Transfusion during Cardiac Surgery , 1992, Annals of Internal Medicine.

[8]  A. Muñoz,et al.  The declining risk of post-transfusion hepatitis C virus infection. , 1992, The New England journal of medicine.

[9]  R. Dodd.  The risk of transfusion-transmitted infection. , 1992, The New England journal of medicine.

[10]  E. Topol,et al.  Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. , 1992, Journal of the American College of Cardiology.

[11]  P. Hartigan,et al.  A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. , 1992, The New England journal of medicine.

[12]  B. Cummins,et al.  Release of creatine kinase-MB and cardiac specific troponin-I following percutaneous transluminal coronary angioplasty. , 1991, European heart journal.

[13]  E. Topol,et al.  Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. , 1991, Journal of the American College of Cardiology.

[14]  L. Klein,et al.  Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. , 1991, Journal of the American College of Cardiology.

[15]  E J Topol,et al.  Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. , 1990, Circulation.

[16]  D. Faxon,et al.  Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. , 1990, Circulation.

[17]  D. Bennett,et al.  Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. , 1990, British heart journal.

[18]  R. Califf,et al.  Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. , 1989, Annals of internal medicine.

[19]  L. Klein,et al.  Adequate heparinization during PTCA: assessment using activated clotting times. , 1989, Catheterization and cardiovascular diagnosis.

[20]  J. Eidt,et al.  Specific Platelet Mediators and Unstable Coronary Artery Lesions: Experimental Evidence and Potential Clinical Implications , 1989, Circulation.

[21]  L Schwartz,et al.  Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. , 1988, The New England journal of medicine.

[22]  S. Ellis,et al.  Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. , 1988, Circulation.

[23]  A. Jaffe,et al.  Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .

[24]  L. Harker,et al.  Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. , 1987, The American journal of cardiology.

[25]  Lynne H. Taylor,et al.  Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. , 1987, Circulation.

[26]  W Siegenthaler,et al.  Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. , 1987, The New England journal of medicine.

[27]  E. Casiglia,et al.  Changes in myoglobin, creatine kinase and creatine kinase-MB after percutaneous transluminal coronary angioplasty for stable angina pectoris. , 1987, The American journal of cardiology.

[28]  E F Cook,et al.  Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. , 1987, The American journal of medicine.

[29]  A. Jaffe,et al.  Paucity of subtle myocardial injury after angioplasty delineated with MB CK. , 1986, Catheterization and Cardiovascular Diagnosis.

[30]  B. Coller,et al.  Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. , 1985, Blood.

[31]  B. Coller.  A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. , 1985, The Journal of clinical investigation.

[32]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .